(6-丁氧基-2-萘)-硼酸(9ci) | 145369-28-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: (6-丁氧基-2-萘)-硼酸(9ci)
• 英文名称: 6-butoxynaphth-2-ylboronic acid
• 英文别名: 6-Butoxynaphthalene-2-boronic acid；(6-butoxynaphthalen-2-yl)boronic acid
• CAS: 145369-28-4
• 化学式: C₁₄H₁₇BO₃
• 分子量: 244.098
• InChiKey: IKDHTYIAXFUCTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (6-丁氧基-2-萘)-硼酸(9ci) 在 palladium on activated charcoal 四(三苯基膦)钯 、 氢气 、 sodium carbonate 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 乙醇 为溶剂， 反应 40.0h， 生成 2-(4-nitrophenyl)-6-butoxynaphthalene
  参考文献：
  名称：

  Synthesis, mesomorphic behaviour and optical anisotropy of some novel materials for nematic mixtures of high birefringenceElectronic supplementary information (ESI) available: experimental procedures for all compounds not already given in this paper. See http://www.rsc.org/suppdata/jm/b4/b400630e/

  摘要：

  结构单元包括核心单元（如苯基、萘基和噻吩基）、连接基团（如乙炔基）、末端取代基（如氰基、异硫氰酸基和氟基）以及侧向氟取代基，已被引入到旨在赋予液晶混合物高双折射率的新材料中。这些材料均通过涉及钯催化的芳基硼酸交叉偶联反应的汇聚合成方法制备而成。材料的介晶行为作为纯材料和混合物进行了研究；一些材料被发现具有极高的液晶相稳定性，而另一些则为非介晶性。材料在液晶宿主混合物中被评估其光学各向异性，所有材料均显示出有希望的高值。

  DOI：

  10.1039/b400630e
• 作为产物：
  描述：

  2-溴-6-正丁氧基萘 、 正丁基锂 、 硼酸三甲酯 、 氯离子 在 氮气 、 乙酸乙酯 、 Sodium sulfate-III 作用下， 以 四氢呋喃 、 正己烷 、 水 为溶剂， 反应 2.0h， 以to provide the title compound (0.397 g, 92% yield)的产率得到(6-丁氧基-2-萘)-硼酸(9ci)
  参考文献：
  名称：

  Indazole compounds and methods of use thereof

  摘要：

  本发明涉及吲唑化合物或其药学上可接受的盐、溶剂合物和水合物。这些吲唑化合物在治疗或预防广泛的疾病和紊乱方面具有实用性，这些疾病和紊乱对激酶的抑制、调节或调控具有反应性，例如炎症性疾病、异常血管生成及相关疾病、癌症、动脉硬化、心血管疾病、肾脏疾病、自身免疫疾病、黄斑变性、与疾病有关的消耗、石棉相关疾病、肺动脉高压、糖尿病、肥胖症、疼痛和其他疾病。因此，本发明还揭示了治疗或预防此类疾病和紊乱的方法，以及包含一种或多种吲唑化合物的药物组成物。本发明部分基于发现一类新型的5-三唑基取代吲唑分子，它们在蛋白激酶调节方面具有强效活性。因此，本发明包括口服活性分子以及可用于治疗与蛋白激酶信号转导相关的疾病或紊乱的肠外活性分子，其剂量或血清浓度较低。

  公开号：

  US20060004043A1

文献信息

• Naphthyl organic compounds
  申请人：The Secretary of State for Defence in Her Britannic Majesty's Government

  公开号：US05496500A1

  公开（公告）日：1996-03-05

  Liquid crystal compounds of formula (I) are described, where formula (I) is given as R.sub.1 --A--(X.sub.m --(B).sub.n --R.sub.2 where A is selected from nathyl, flourinated naphthyl, brominated naphthyl, B is selected from phenyl, methylated phenyl, brominated phenyl, fluorinated phenyl, thiophene, pyrimidine and pyridine, R.sub.1 and R.sub.2 are independently selected from alkyl, alkoxy, alkynyl, thioalkyl, Br, CN, SCN, NCS, perfluoroalkyl, perfluoroalkoxy and hydrogen, X is selected from C.tbd.C, COO and C.tbd.C, m is 0 or 1, n is 0 or 1 where m is 1 and n is 0 where m is 0; provided that where A is naphthyl, n is 1 and m is 0 then B is selected from methylated phenyl, brominated phenyl, thiophene, pyrimidine and pyridine; and further provided that where A is naphthyl, X is C.tbd.C, m is 1 and n is 1, then B is selected from thiophene, pyrimidine and pyridine. Also described are liquid crystal compounds suitable for inclusion in devices utilizing pretransitional characteristics of liquid crystalline materials in the isotropic phase and described by formula (II): R.sub.3 --J--(Y).sub.p --(Z).sub.q --R.sub. 4, where J is selected from nathyl, fluorinated naphthyl, brominated naphthyl, Z is selected from phenyl, methylated phenyl, brominated phenyl, fluorinated phenyl, thiophene, pyrimidine and pyridine, R.sub.1 and R.sub.2 are independently selected from alkyl, alkoxy, alkynyl, thioalkyl, Br, CN, SCN, NCS, perfluoroalkyl, perfluoroalkoxy and hydrogen, Y is selected from C.dbd.C, COO and C.dbd.C, p is 0 or 1, q is 0 or 1 where p is 1 and q is 0 where p is 0.

  描述了化学式（I）的液晶化合物，其中化学式（I）给出为R.sub.1 --A--(X.sub.m --(B).sub.n --R.sub.2，其中A选自nathyl，氟化naphthyl，溴化naphthyl，B选自苯基，甲基化苯基，溴化苯基，氟化苯基，噻吩，嘧啶和吡啶，R.sub.1和R.sub.2分别选自烷基，烷氧基，烷炔基，硫烷基，Br，CN，SCN，NCS，全氟烷基，全氟烷氧基和氢，X选自C.tbd.C，COO和C.tbd.C，m为0或1，n为0或1，其中m为1且n为0时，m为0时n为0；但要求当A为naphthyl时，n为1且m为0时，B选自甲基化苯基，溴化苯基，噻吩，嘧啶和吡啶；进一步要求当A为naphthyl，X为C.tbd.C，m为1且n为1时，B选自噻吩，嘧啶和吡啶。还描述了适用于包含在利用液晶材料各向同性相的前过渡特性的器件中的液晶化合物，其化学式为（II）：R.sub.3 --J--(Y).sub.p --(Z).sub.q --R.sub.4，其中J选自nathyl，氟化naphthyl，溴化naphthyl，Z选自苯基，甲基化苯基，溴化苯基，氟化苯基，噻吩，嘧啶和吡啶，R.sub.1和R.sub.2分别选自烷基，烷氧基，烷炔基，硫烷基，Br，CN，SCN，NCS，全氟烷基，全氟烷氧基和氢，Y选自C.dbd.C，COO和C.dbd.C，p为0或1，q为0或1，其中p为1且q为0时，p为0时q为0。
• Novel and Unexpected Deamination during the Palladium-Catalysed Cross-Coupling of Haloanilines and Arylboronic Acids
  作者：Michael Hird、Alexander J. Seed、Kenneth J. Toyne

  DOI：10.1055/s-1999-2638

  日期：1999.4

  Palladium-catalysed cross-coupling reactions involving haloanilines and arylboronic acids produce the expected biaryl products, but additionally a substantial quantity of the corresponding deaminated biaryl is also generated which constitutes a novel synthetic methodology.

  钯催化的卤代苯胺和芳基硼酸交叉偶联反应产生了预期的双芳基产物，但同时也产生了大量相应的脱氨基双芳基，这是一种新颖的合成方法。
• INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Bhagwat Shripad S.

  公开号：US20090099178A1

  公开（公告）日：2009-04-16

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseases or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶剂合物和水合物。这些吲唑化合物在治疗或预防许多对激酶的抑制、调节或调控具有反应性的疾病和障碍方面具有用途，例如炎症性疾病、异常血管生成及相关疾病、癌症、动脉粥样硬化、心血管疾病、肾脏疾病、自身免疫疾病、黄斑变性、与疾病相关的消耗、石棉相关疾病、肺动脉高压、糖尿病、肥胖症、疼痛等。因此，本发明还揭示了治疗或预防这些疾病和障碍的方法，以及包含一种或多种吲唑化合物的制药组合物。本发明部分基于发现一类新型的5-三唑基取代吲唑分子，这些分子在调节蛋白激酶方面具有强效活性。因此，本发明包括口服活性分子和经肠道给药的活性分子，可用于治疗与蛋白激酶信号转导相关的疾病或障碍，且可用较低剂量或血清浓度。
• Synthesis, mesomorphic behaviour and optical anisotropy of some novel materials for nematic mixtures of high birefringenceElectronic supplementary information (ESI) available: experimental procedures for all compounds not already given in this paper. See http://www.rsc.org/suppdata/jm/b4/b400630e/
  作者：Michael Hird、Kenneth J. Toyne、John W. Goodby、George W. Gray、Victoria Minter、Rachel P. Tuffin、Damien G. McDonnell

  DOI：10.1039/b400630e

  日期：——

  Structural moieties including core units (such as phenyl, naphthyl and thiophenyl), linking groups (such as ethynyl), terminal substituents (such as cyano, isothiocyanato and fluoro), and lateral fluoro substituents have been incorporated into novel materials designed to confer a high birefringence on nematic mixtures. The materials have all been prepared through convergent syntheses involving palladium-catalysed cross-coupling reactions of arylboronic acids. The materials were examined for their mesomorphic behaviour as neat materials and as mixtures; some materials were found to have extremely high nematic phase stability, and others were non-mesogenic. The materials were evaluated in nematic host mixtures for their optical anisotropy, and they were all found to show promisingly high values.

  结构单元包括核心单元（如苯基、萘基和噻吩基）、连接基团（如乙炔基）、末端取代基（如氰基、异硫氰酸基和氟基）以及侧向氟取代基，已被引入到旨在赋予液晶混合物高双折射率的新材料中。这些材料均通过涉及钯催化的芳基硼酸交叉偶联反应的汇聚合成方法制备而成。材料的介晶行为作为纯材料和混合物进行了研究；一些材料被发现具有极高的液晶相稳定性，而另一些则为非介晶性。材料在液晶宿主混合物中被评估其光学各向异性，所有材料均显示出有希望的高值。
• Indazole compounds and methods of use thereof
  申请人：Bhagwat S. Shripad

  公开号：US20060004043A1

  公开（公告）日：2006-01-05

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseses or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶剂合物和水合物。这些吲唑化合物在治疗或预防广泛的疾病和紊乱方面具有实用性，这些疾病和紊乱对激酶的抑制、调节或调控具有反应性，例如炎症性疾病、异常血管生成及相关疾病、癌症、动脉硬化、心血管疾病、肾脏疾病、自身免疫疾病、黄斑变性、与疾病有关的消耗、石棉相关疾病、肺动脉高压、糖尿病、肥胖症、疼痛和其他疾病。因此，本发明还揭示了治疗或预防此类疾病和紊乱的方法，以及包含一种或多种吲唑化合物的药物组成物。本发明部分基于发现一类新型的5-三唑基取代吲唑分子，它们在蛋白激酶调节方面具有强效活性。因此，本发明包括口服活性分子以及可用于治疗与蛋白激酶信号转导相关的疾病或紊乱的肠外活性分子，其剂量或血清浓度较低。